EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel Alkynylbenzene Scaffold-Based PTPN2-Selective Degrader PD-305 with Exceptional Potency and In Vivo Efficacy

Linghao Hu iD, Liting Guo, Mengxi Zhang, Jingxun Wei, Qi Huang, Haowen Chen, Ying Liu, Xiaomin Xu, Lei Xu, Yubo Zhou, Jia Li, Mingliang Wang iD

Journal of Medicinal Chemistry · 28.05.2026 · 69 (10) · 11998-12019

DOI: 10.1021/acs.jmedchem.5c03643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 14.05.2026. Verfasst von Linghao Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 2, Antineoplastic Agents, Alkynes, Drug Discovery. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality, Basic and Applied Basic Research Foundation of Guangdong Province, Shanghai Science and Technology Development Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted degradation of PTPN2 is an attractive cancer immunotherapy strategy. However, unfavorable physicochemical properties limit the development of current PTPN2 degraders. In this study, using a ring-opening scaffold-hopping strategy, we identified a class of alkyne-containing PTPN2 ligands, which were subsequently employed for PROTAC design. Through optimizing linkers and CRBN ligands, we obtained PD-305, featuring a rigid linker and a naphtholactam-based ligand. PD-305 exhibits subnanomolar degradation potency (DC50 = 0.25 nM, 868-fold superior to the previously discovered PVD-06) and good subtype selectivity (PTPN2/PTPN1 selectivity >20-fold). Compared to previous PTPN2 degraders, it displays lower molecular weight, fewer hydrogen bond donors/acceptors, and a reduced cLogP. PD-305 exhibited nanomolar antiproliferation potency in the IFN-γ stimulated HT-29 cell line, nearly 80-fold more potent than the clinical candidate AC484. Moreover, it possessed excellent in vivo PTPN2 degradation potency and effectively suppressed tumor growth in mice. Collectively, PD-305 is a promising lead compound worthy of further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Tyrosine Phosphatase, Non-Receptor Type 2Antineoplastic AgentsAlkynesDrug DiscoveryHumansAnimalsMiceCell ProliferationProteolysis Targeting ChimeraStructure-Activity RelationshipHT29 CellsProteolysis

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 2Antineoplastic AgentsAlkynesPTPN2 protein, humanProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • School of Pharmaceutical Sciences, Southern Medical University, No.1023, South Shatai Road, Baiyun District, Guangzhou, Guangdong 510515, China.
  • Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • School of Pharmacy, University of Chinese Academy of Sciences, Beijing 100049, China.
  • School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau, Macau SAR 999078, China.

ORCID-Profile: Linghao Hu, Mingliang Wang

Förderung

  • Natural Science Foundation of Shanghai Municipality
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Shanghai Science and Technology Development Foundation
  • Natural Science Foundation of Shandong Province
  • High-level Innovative Research Institute, Department of Science and Technology of Guangdong Province

Zitieren

APA

Hu, L., Guo, L., Zhang, M., Wei, J., Huang, Q., Chen, H., Liu, Y., Xu, X., Xu, L., Zhou, Y., Li, J., & Wang, M. (2026). Discovery of Novel Alkynylbenzene Scaffold-Based PTPN2-Selective Degrader PD-305 with Exceptional Potency and In Vivo Efficacy. Journal of Medicinal Chemistry, 69(10), 11998-12019. https://doi.org/10.1021/acs.jmedchem.5c03643

Vancouver

Hu L, Guo L, Zhang M, Wei J, Huang Q, Chen H, et al. Discovery of Novel Alkynylbenzene Scaffold-Based PTPN2-Selective Degrader PD-305 with Exceptional Potency and In Vivo Efficacy. Journal of Medicinal Chemistry. 2026;69(10):11998-12019. doi:10.1021/acs.jmedchem.5c03643

BibTeX
@article{Hu2026,
  author = {Hu, Linghao and Guo, Liting and Zhang, Mengxi and Wei, Jingxun and Huang, Qi and Chen, Haowen and Liu, Ying and Xu, Xiaomin and Xu, Lei and Zhou, Yubo and Li, Jia and Wang, Mingliang},
  title = {Discovery of Novel Alkynylbenzene Scaffold-Based PTPN2-Selective Degrader PD-305 with Exceptional Potency and In Vivo Efficacy},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {10},
  pages = {11998--12019},
  doi = {10.1021/acs.jmedchem.5c03643}
}
Kostenlos starten →